CASI Pharma上涨15％

StephenW

CASI Pharma up 15%
Nov. 30, 2018 11:26 AM ET|About: CASI Pharmaceuticals (CASI)|By: Douglas W. House, SA News Editor

Thinly traded micro cap CASI Pharmaceuticals (CASI +15.1%) clears brief consolidation on average volume. Shares have rallied 60% in a month.

In late October, it acquired Laurus Labs' U.S. marketing authorization (ANDA) for its generic version of tenofovir disoproxil fumarate (TDF) for the treatment of hepatitis B virus (HBV) infection for $700K upfront and up to $2.3M in milestones. It plans to commercialize the product in China.

Yesterday after the close, the SEC declared its prospectus for the resale of up to ~9.1M common shares from existing investors effective.

CASI Pharma上涨15％
2018年11月30日东部时间上午11:26 |关于：CASI Pharmaceuticals（CASI）|作者：Douglas W. House，SA新闻编辑

交易清淡的微型上限CASI Pharmaceuticals（CASI + 15.1％）清除了平均成交量的短暂整合。 股价在一个月内上涨了60％。

10月下旬，它获得了Laurus Labs的美国上市许可（ANDA），因为其通用版替诺福韦地富马酸盐富马酸盐（TDF）用于治疗乙型肝炎病毒（HBV）感染，预计价格为70万美元，里程碑价格高达230万美元。 它计划将产品在中国商业化。

昨天收盘后，美国证券交易委员会宣布其现有投资者转售高达约910万股普通股的招股说明书生效。